Our co-founder Prof. Dr. Alexander Steinkasserer talked to Laborjournal about the serendipitous discovery of sCD83’s ability to stimulate hair growth.
Prof. Dr. Steinkasserer and his team have been studying the immune-regulating protein CD83 for over 20 years. During studies evaluating the wound-healing properties of soluble CD83, they noticed a marked increase in hair growth when wounds were treated with sCD83.
With this finding, the idea for Mallia Therapeutics was born. After successfully securing our seed financing, we are excited to advance to our next phase and are currently seeking Series A financing to move this exciting finding into the clinic.
